-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

Benzinga·05/06/2026 12:09:38
Listen to the news
HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.